Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, announced today that the company will make three presentations at the Clinical Trials in Alzheimer's Disease (CTAD) Meeting being held in Barcelona November 5-7, 2015.
An oral presentation "RVT-101: review of the preclinical and clinical results and status of the development program" will be made by Dr. Lawrence T. Friedhoff, Chief Development Officer on Saturday, November 7, 2015.
In addition, the company will make the following poster presentations:
- • "PET studies with RVT-101 in healthy volunteers demonstrate high occupancy of the 5HT6 receptor" on November 6, 2015
- • "Safety of the 5HT6 antagonist, RVT-101 in patients with Alzheimer's Disease: summary of Phase 2 clinical trials" on November 5, 2015
RVT-101 is an orally administered, potent antagonist of the 5HT6 receptor. Antagonism of the 5HT6 receptor is a novel mechanism of action that promotes the release of acetylcholine and other neurotransmitters thought to improve cognition and function in patients suffering from Alzheimer's disease and other forms of dementia. RVT-101 has been studied in 13 clinical trials and dosed in over 1,250 human subjects with a favorable safety and tolerability profile. Axovant commenced the MINDSET Study in October 2015, pursuant to a Special Protocol Assessment (SPA) agreement with FDA. MINDSET is a confirmatory phase 3 clinical study testing RVT-101 on a background of donepezil therapy in mild-to-moderate Alzheimer's disease patients.
RVT-101 is an investigational new drug candidate and is not approved for any indication in any markets.
Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of the disease.